查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2040533

注射給藥裝置市場規模、佔有率和趨勢分析報告：按產品、治療應用、最終用途、地區和細分市場分類（2026-2033 年）

Injectable Drug Delivery Devices Market Size, Share & Trends Analysis Report By Product, By Therapeutic Use, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

注射式藥物輸送裝置市場概述

2025年全球注射式藥物輸送裝置的市場規模估計為1,147億美元，預計到2033年將達到2,365億美元。

從2026年到2033年，該市場預計將以9.6%的複合年成長率成長。這一顯著成長是由各種醫療保健機構對先進、高效且易於使用的藥物輸送解決方案日益成長的需求所驅動的。

推動這一趨勢的主要因素包括需要頻繁注射的慢性疾病（例如糖尿病、癌症和自體免疫疾病）盛行率的上升。此外，不斷提升安全性、精確性和患者舒適度的技術創新，以及對便捷注射裝置（例如自動注射器和筆式注射器）日益成長的需求，也促進了這一成長趨勢。生物製藥的快速發展、居家照護的普及以及減少住院次數的趨勢，也推動了該市場的成長。

影響成長的另一個因素是各種醫療機構對先進、高效且易於使用的藥物輸送解決方案的需求不斷成長。其中幾個關鍵因素發揮作用，包括需要頻繁注射的慢性疾病（例如糖尿病、癌症和自體免疫疾病）的盛行率不斷上升。此外，人們對便利注射裝置（例如自動注射器和筆式注射器）的需求也在不斷成長，同時，不斷提高安全性、準確性和患者舒適度的技術也在持續進步。此外，生物製藥創新方面的進步、居家照護的興起以及減少住院次數的趨勢也促進了這一有利的市場趨勢。

根據世界衛生組織（世衛組織）的數據，2022年全球新增癌症病例約2,000萬例，死亡人數達970萬人。預計到2050年，這些數字將激增77%，全球整體癌症病例將超過3,500萬例。同樣，心血管疾病（CVD），包括冠狀動脈疾病、腦血管疾病和風濕性心臟疾病，仍然是全球首要死因，每年約奪去1790萬人的生命。

慢性疾病通常需要長期治療，而對於許多患者來說，持續進行複雜的注射治療是一項挑戰。先進的注射給藥裝置透過簡化給藥流程、減少注射頻率和最大程度地減少錯誤，幫助克服了這些挑戰。自動注射器和筆式注射器簡化了注射過程，並穩定了生物製藥和特殊藥物的給藥。許多新一代裝置還具有劑量提醒、即時監測連接和數位追蹤等功能，所有這些都有助於提高患者的用藥依從性，並使其能夠更有效地管理治療計劃。提高用藥依從性不僅能帶來更好的健康結果，還能減少疾病復發、急診就診次數和整體醫療成本。

根據世界衛生組織（世衛組織，2024）的報告，慢性病仍然是全球最大的健康問題，也是成長最快的挑戰。慢性病約佔全球整體所有死亡人數的75%。非傳染性疾病（NCDs），如心血管疾病、癌症、慢性呼吸系統疾病和糖尿病，每年導致約4,100萬人死亡。其中超過77%的死亡病例集中在中低收入國家。來自《2024年全球疾病負擔報告》（GBD 2024）的數據顯示，全球有超過13億人患有至少一種需要持續治療的慢性病，​​其中許多人依賴注射藥物，例如胰島素、單株抗體和生物製劑。不斷上升的肥胖率、久坐的生活方式和人口老化加劇了這個問題。

目錄

第1章：調查方法和範圍

第2章執行摘要

第2章 注射給藥裝置市場：產品分析

  • 產品特定波動分析、市場佔有率、2025 年及 2033 年
  • 注射式藥物輸送裝置的市場估算與預測（按產品、銷售量計）
  • 市場規模、預測與趨勢分析，2021-2033年

第3章：注射式藥物輸送裝置市場：治療應用估算與趨勢分析

  • 按治療區域和市場佔有率分類的波動分析（2025 年和 2033 年）
  • 注射式藥物輸送裝置的市場估算與預測（依治療應用、按單位）
  • 市場規模、預測與趨勢分析，2021-2033年
    • 自體免疫疾病
    • 內分泌疾病
    • 腫瘤學
    • 肥胖
    • 糖尿病
    • 其他

第4章 注射給藥裝置市場：依最終用途分析

  • 基於最終用途的波動分析、市場佔有率、2025 年和 2033 年
  • 注射式藥物傳輸裝置的市場估算與預測（依應用領域，單位：台）
  • 市場規模、預測與趨勢分析，2021-2033年

第5章 注射給藥裝置市場：區域估算與趨勢分析

  • 注射式藥物輸送裝置市場：區域展望
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞洲
    • 中國
    • 日本
    • 印度
    • 泰國
    • 韓國
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第6章 注射給藥裝置市場：競爭分析

  • 公司分類
  • 參與企業概況
  • 財務業績
  • Product Offerings
  • 公司市場分析
  • 企業市場占有率分析，2025 年（%）
  • 策略規劃
    • 產品上市及核准
    • 夥伴關係與合作
    • 併購
    • 業務拓展
    • 其他
  • 公司簡介
    • Novo Nordisk A/S
    • Sanofi
    • Eli Lilly and Company
    • AstraZeneca plc
    • Pfizer, Inc.
    • Merck KGaA
    • Teva Pharmaceuticals
    • Amgen, Inc.
    • Ferring Pharmaceuticals
    • AbbVie, Inc.
Product Code: 978-1-68048-GVR-8

Injectable Drug Delivery Devices Market Summary

The global injectable drug delivery devices market size was estimated at USD 114.7 billion in 2025 and is projected to reach USD 236.5 billion by 2033, growing at a CAGR of 9.6% from 2026 to 2033. This significant growth is fueled by an increasing need for advanced, effective, and user-friendly drug delivery solutions in various healthcare environments.

Key factors include the rising incidence of chronic diseases like diabetes, cancer, and autoimmune disorders that necessitate frequent injections. In addition, there is a growing preference for convenient injection instruments such as autoinjectors and pen injectors, alongside continuous technological innovations that improve safety, accuracy, and patient comfort. Moreover, the surge in biological developments, a shift toward home-based care, and an emphasis on minimizing hospital visits are all contributing to this upward trend in the market.

Another factor that influences the growth is the increasing demand for advanced, effective, and user-friendly drug delivery solutions in a variety of healthcare settings. Several key factors are at play, including the rising prevalence of chronic diseases like diabetes, cancer, and autoimmune disorders that require frequent injections. There's also a growing preference for convenient injection devices such as autoinjectors and pen injectors, coupled with ongoing technological advancements that enhance safety, accuracy, and patient comfort. In addition, the rise in biopharmaceutical innovations, a shift towards home-based care, and a focus on reducing hospital visits are all contributing to this positive market trend.

According to the World Health Organization (WHO), in 2022, there were approximately 20 million new cancer cases and 9.7 million deaths. By 2050, this figure is expected to surge by 77%, reaching over 35 million cases globally. Similarly, cardiovascular diseases (CVDs), such as coronary heart disease, cerebrovascular disease, and rheumatic heart disease, remain the leading cause of death worldwide, claiming an estimated 17.9 million lives annually.

Chronic diseases often require long-term treatment, making it challenging for many patients to stick to complex injectable regimens. Advanced drug delivery devices for injections help overcome these obstacles by making administration easier, reducing the frequency of doses, and minimizing errors. Autoinjectors and pen injectors streamline the injection process, promoting consistent dosing of biologics and specialty medications. Many next-generation devices also feature built-in dose reminders, connectivity for real-time monitoring, and digital tracking, all of which enhance adherence and enable patients to manage their treatment schedules more effectively. When adherence improves, it not only leads to better health outcomes but also decreases disease flare-ups, emergency visits, and overall healthcare costs.

Chronic diseases remain the leading and fastest-growing global health issue, responsible for nearly 75% of all deaths worldwide, as reported by the World Health Organization (WHO, 2024). Noncommunicable diseases (NCDs) like cardiovascular diseases, cancer, chronic respiratory illnesses, and diabetes cause approximately 41 million deaths annually. Low- and middle-income countries account for more than 77% of this mortality. The Global Burden of Disease (GBD) 2024 data indicate that over 1.3 billion people worldwide live with at least one chronic condition requiring continuous management, many of whom depend on injectable treatments such as insulin, monoclonal antibodies, and biologics. The increasing rates of obesity, sedentary lifestyles, and aging populations continue to intensify this issue.

Global Injectable Drug Delivery Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 - 2033. For this study, Grand View Research has segmented the global injectable drug delivery devices market report based on product, therapeutic use, end use, and region:

  • Product Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
  • Injectors
    • GLP-1 Agonists
    • Hormone Therapies
    • Biologics
    • Others
  • Pen
    • GLP-1 Agonists
    • Insulin
    • Hormone Therapies
    • Others
  • Therapeutic Use Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
  • Autoimmune Disorders
  • Hormonal Disorders
  • Oncology
  • Obesity
  • Diabetes Mellitus
  • Others
  • End Use Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
  • Hospitals
  • Homecare Settings
  • Others
  • Regional Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Norway
    • Sweden
    • Denmark
  • Asia
    • China
    • Japan
    • India
    • Thailand
    • South Korea
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Product
    • 1.2.2. Drug Type
    • 1.2.3. Therapeutic Use
    • 1.2.4. End Use
  • 1.3. Estimation and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Materials & Third-Party Perspectives
    • 1.5.4. Primary Research
  • 1.6. Information or Data Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
      • 1.8.1.1. Research Scope and Assumptions
      • 1.8.1.2. Research Methodology and Assumptions
    • 1.8.2. Volume Price Analysis
    • 1.8.3. CDMO injectable drug delivery devices Market
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations
  • 1.11. Objectives
    • 1.11.1. Objective 1
    • 1.11.2. Objective 2
    • 1.11.3. Objective 3

Chapter 2. Executive Summary

  • 2.1. Market Snapshot (Regional)
  • 2.2. Segment Snapshot (Product)
  • 2.3. Segment Snapshot (Therapeutic Use)
  • 2.4. Segment Snapshot (End-use)
  • 2.5. Market Concentration
  • 2.6. Injectable Drug Delivery Devices Market Variables and Trends Market Lineage Outlook
  • 2.7. Market Dynamics
    • 2.7.1. Market Driver Impact Analysis
    • 2.7.2. Market Restraint Analysis
    • 2.7.3. Market Opportunity Analysis
  • 2.8. Industry Analysis Tools
    • 2.8.1. Porter's Five Forces Analysis
    • 2.8.2. Macroeconomic Analysis
  • 2.9. List of CDMO Manufacturers and Supplied Injectable Drug Delivery Devices to Companies
    • 2.9.1. List of In-House Manufacturers of Injectable Drug Delivery Devices
    • 2.9.2. Qualitative Insights on Potential Impact of New Injectables or Oral Drugs and Development of Multi-Dose Devices, by Region
    • 2.9.3. North America
    • 2.9.4. Europe
    • 2.9.5. Asia
  • 2.10. Global CDMO Injectable Drug Delivery Devices Market, by Product, 2021 - 2033 (value in USD Billion and Volume in Units Sold)
    • 2.10.1. Global CDMO Injectable Drug Delivery Devices Market, by Product, 2021 - 2033 (USD Billion)
    • 2.10.2. Global CDMO Injectable Drug Delivery Devices Market, by Product, 2021 - 2033 (Units)

Chapter 2. Injectable Drug Delivery Devices Market: Product Analysis

  • 2.1. Product Movement Analysis & Market Share, 2025 & 2033
  • 2.2. Injectable Drug Delivery Devices Market Estimates & Forecast, by Product (USD Billion, Units)
  • 2.3. Market Size & Forecasts and Trend Analysis, 2021 - 2033
    • 2.3.1. Injectors
      • 2.3.1.1. Injectors Market, 2021 - 2033 (USD Billion, Units)
      • 2.3.1.2. GLP-1 Agonists
        • 2.3.1.2.1. GLP-1 Agonists Market, 2021 - 2033 (USD Billion, Units)
      • 2.3.1.3. Hormone Therapies
        • 2.3.1.3.1. Hormone Therapies Market, 2021 - 2033 (USD Billion, Units)
      • 2.3.1.4. Biologics
        • 2.3.1.4.1. Biologics Market, 2021 - 2033 (USD Billion, Units)
      • 2.3.1.5. Others
        • 2.3.1.5.1. Others Market, 2021 - 2033 (USD Billion, Units)
    • 2.3.2. Pens
      • 2.3.2.1. Pens Market, 2021 - 2033 (USD Billion, Units)
      • 2.3.2.2. GLP-1 Agonists
        • 2.3.2.2.1. GLP-1 Agonists Market, 2021 - 2033 (USD Billion, Units)
      • 2.3.2.3. Insulin
        • 2.3.2.3.1. Insulin Market, 2021 - 2033 (USD Billion, Units)
      • 2.3.2.4. Hormone Therapies
        • 2.3.2.4.1. Hormone Therapies Market, 2021 - 2033 (USD Billion, Units)
      • 2.3.2.5. Others
        • 2.3.2.5.1. Other Market Estimates & Forecasts, 2021 - 2033 (USD Billion, Units)

Chapter 3. Injectable Drug Delivery Devices Market: Therapeutic Use Estimates & Trend Analysis

  • 3.1. Therapeutic Area Movement Analysis & Market Share, 2025 & 2033
  • 3.2. Injectable Drug Delivery Devices Market Estimates & Forecast, by Therapeutic Use (USD Billion, Units)
  • 3.3. Market Size & Forecasts and Trend Analysis, 2021 - 2033
    • 3.3.1. Autoimmune Disorders
      • 3.3.1.1. Autoimmune Disorders Market, 2021 - 2033 (USD Billion, Units)
    • 3.3.2. Hormonal Disorders
      • 3.3.2.1. Hormonal Disorders Market, 2021 - 2033 (USD Billion, Units)
    • 3.3.3. Oncology
      • 3.3.3.1. Oncology Market, 2021 - 2033 (USD Billion, Units)
    • 3.3.4. Obesity
      • 3.3.4.1. Obesity Market, 2021 - 2033 (USD Billion, Units)
    • 3.3.5. Diabetes Mellitus
      • 3.3.5.1. Diabetes Mellitus Market, 2021 - 2033 (USD Billion, Units)
    • 3.3.6. Others
      • 3.3.6.1. Others Market, 2021 - 2033 (USD Billion, Units)

Chapter 4. Injectable Drug Delivery Devices Market: End Use Analysis

  • 4.1. End Use Movement Analysis & Market Share, 2025 & 2033
  • 4.2. Injectable Drug Delivery Devices Market Estimates & Forecast, by End Use (USD Billion, Units)
  • 4.3. Market Size & Forecasts and Trend Analysis, 2021 - 2033
    • 4.3.1. Hospitals
      • 4.3.1.1. Hospitals Market, 2021 - 2033 (USD Billion, Units)
    • 4.3.2. Homecare Settings
      • 4.3.2.1. Homecare Settings Market, 2021 - 2033 (USD Billion, Units)
    • 4.3.3. Others
      • 4.3.3.1. Others Market, 2021 - 2033 (USD Billion, Units)

Chapter 5. Injectable Drug Delivery Devices Market: Regional Estimates & Trend Analysis

  • 5.1. Injectable Drug Delivery Devices Market: Regional Outlook
  • 5.2. North America
    • 5.2.1. North America Injectable Drug Delivery Devices Market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.2.2. U.S.
      • 5.2.2.1. Competitive Scenario
      • 5.2.2.2. Regulatory framework
      • 5.2.2.3. Reimbursement Structure
      • 5.2.2.4. U.S. Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.2.3. Canada
      • 5.2.3.1. Competitive Scenario
      • 5.2.3.2. Regulatory framework
      • 5.2.3.3. Reimbursement Structure
      • 5.2.3.4. Canada Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.2.4. Mexico
      • 5.2.4.1. Competitive Scenario
      • 5.2.4.2. Regulatory framework
      • 5.2.4.3. Reimbursement Structure
      • 5.2.4.4. Mexico Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.3. Europe
    • 5.3.1. Europe Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.3.2. UK
      • 5.3.2.1. Competitive Scenario
      • 5.3.2.2. Regulatory framework
      • 5.3.2.3. Reimbursement Structure
      • 5.3.2.4. UK Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.3.3. Germany
      • 5.3.3.1. Competitive Scenario
      • 5.3.3.2. Regulatory framework
      • 5.3.3.3. Reimbursement Structure
      • 5.3.3.4. Germany Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.3.4. France
      • 5.3.4.1. Competitive Scenario
      • 5.3.4.2. Regulatory framework
      • 5.3.4.3. Reimbursement Structure
      • 5.3.4.4. France Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.3.5. Italy
      • 5.3.5.1. Competitive Scenario
      • 5.3.5.2. Regulatory framework
      • 5.3.5.3. Reimbursement Structure
      • 5.3.5.4. Italy Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.3.6. Spain
      • 5.3.6.1. Competitive Scenario
      • 5.3.6.2. Regulatory framework
      • 5.3.6.3. Reimbursement Structure
      • 5.3.6.4. Spain Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.3.7. Norway
      • 5.3.7.1. Competitive Scenario
      • 5.3.7.2. Regulatory framework
      • 5.3.7.3. Reimbursement Structure
      • 5.3.7.4. Norway Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.3.8. Sweden
      • 5.3.8.1. Competitive Scenario
      • 5.3.8.2. Regulatory framework
      • 5.3.8.3. Reimbursement Structure
      • 5.3.8.4. Sweden Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.3.9. Denmark
      • 5.3.9.1. Competitive Scenario
      • 5.3.9.2. Regulatory framework
      • 5.3.9.3. Reimbursement Structure
      • 5.3.9.4. Denmark Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.4. Asia
    • 5.4.1. Asia Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.4.2. China
      • 5.4.2.1. Competitive Scenario
      • 5.4.2.2. Regulatory framework
      • 5.4.2.3. Reimbursement Structure
      • 5.4.2.4. China Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.4.3. Japan
      • 5.4.3.1. Competitive Scenario
      • 5.4.3.2. Regulatory framework
      • 5.4.3.3. Reimbursement Structure
      • 5.4.3.4. Japan Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.4.4. India
      • 5.4.4.1. Competitive Scenario
      • 5.4.4.2. Regulatory framework
      • 5.4.4.3. Reimbursement Structure
      • 5.4.4.4. India Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.4.5. Thailand
      • 5.4.5.1. Competitive Scenario
      • 5.4.5.2. Regulatory framework
      • 5.4.5.3. Reimbursement Structure
      • 5.4.5.4. Thailand Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.4.6. South Korea
      • 5.4.6.1. Competitive Scenario
      • 5.4.6.2. Regulatory framework
      • 5.4.6.3. Reimbursement Structure
      • 5.4.6.4. South Korea Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.4.7. Saudi Arabia
      • 5.4.7.1. Competitive Scenario
      • 5.4.7.2. Regulatory framework
      • 5.4.7.3. Reimbursement Structure
      • 5.4.7.4. Saudi Arabia Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.4.8. UAE
      • 5.4.8.1. Competitive Scenario
      • 5.4.8.2. Regulatory framework
      • 5.4.8.3. Reimbursement Structure
      • 5.4.8.4. UAE Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 5.4.9. Kuwait
      • 5.4.9.1. Competitive Scenario
      • 5.4.9.2. Regulatory framework
      • 5.4.9.3. Reimbursement Structure
      • 5.4.9.4. Kuwait Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)

Chapter 6. Injectable Drug Delivery Devices Market: Competitive Analysis

  • 6.1. Company Categorization
  • 6.2. Participant's Overview
  • 6.3. Financial Performance
  • 6.4. Product Offerings
  • 6.5. Company Market Position Analysis
  • 6.6. Company Market Share Analysis, 2025 (%)
  • 6.7. Strategy Mapping
    • 6.7.1. Product Launches & Approvals
    • 6.7.2. Partnerships & Collaborations
    • 6.7.3. Mergers & Acquisitions
    • 6.7.4. Expansions
    • 6.7.5. Others
  • 6.8. Company Profiles
    • 6.8.1. Novo Nordisk A/S
      • 6.8.1.1. Company Overview
      • 6.8.1.2. Financial Performance
      • 6.8.1.3. Product Benchmarking
      • 6.8.1.4. Strategic Initiatives
    • 6.8.2. Sanofi
      • 6.8.2.1. Company Overview
      • 6.8.2.2. Financial Performance
      • 6.8.2.3. Product Benchmarking
      • 6.8.2.4. Strategic Initiatives
    • 6.8.3. Eli Lilly and Company
      • 6.8.3.1. Company Overview
      • 6.8.3.2. Financial Performance
      • 6.8.3.3. Product Benchmarking
      • 6.8.3.4. Strategic Initiatives
    • 6.8.4. AstraZeneca plc
      • 6.8.4.1. Company Overview
      • 6.8.4.2. Financial Performance
      • 6.8.4.3. Product Benchmarking
      • 6.8.4.4. Strategic Initiatives
    • 6.8.5. Pfizer, Inc.
      • 6.8.5.1. Company Overview
      • 6.8.5.2. Financial Performance
      • 6.8.5.3. Product Benchmarking
      • 6.8.5.4. Strategic Initiatives
    • 6.8.6. Merck KGaA
      • 6.8.6.1. Company Overview
      • 6.8.6.2. Financial Performance
      • 6.8.6.3. Product Benchmarking
      • 6.8.6.4. Strategic Initiatives
    • 6.8.7. Teva Pharmaceuticals
      • 6.8.7.1. Company Overview
      • 6.8.7.2. Financial Performance
      • 6.8.7.3. Product Benchmarking
      • 6.8.7.4. Strategic Initiatives
    • 6.8.8. Amgen, Inc.
      • 6.8.8.1. Company Overview
      • 6.8.8.2. Financial Performance
      • 6.8.8.3. Product Benchmarking
      • 6.8.8.4. Strategic Initiatives
    • 6.8.9. Ferring Pharmaceuticals
      • 6.8.9.1. Company Overview
      • 6.8.9.2. Financial Performance
      • 6.8.9.3. Product Benchmarking
      • 6.8.9.4. Strategic Initiatives
    • 6.8.10. AbbVie, Inc.
      • 6.8.10.1. Company Overview
      • 6.8.10.2. Financial Performance
      • 6.8.10.3. Product Benchmarking
      • 6.8.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Estimated number of new cancer cases for all cancer types from 2025 to 2030, Incidence, Both sexes, age [0-85+]
  • Table 3 Estimated global prevalence and mortality of major chronic diseases, 2025
  • Table 4 Comparison of injectable drug delivery devices and conventional therapies: cost and long-term value
  • Table 5 Device preferences for top biologic classes
  • Table 6 Regional comparison of injectable drug delivery ecosystem maturity in North America
  • Table 7 Europe diabetes burden and prevalence trends (2000, 2011, 2024, and 2030 estimates)
  • Table 8 Major companies offering autoinjectors
  • Table 9 Key companies and their prefilled/smart pen product offerings
  • Table 10 Global injectable drug delivery devices market revenue estimates and forecast, by product, 2021 - 2033 (USD Billion, Units)
  • Table 11 Global injectable drug delivery devices market revenue estimates and forecast, by drug type, 2021 - 2033 (USD Billion, Units)
  • Table 12 Global injectors market, by drug type, 2021 - 2033 (USD Billion, Units)
  • Table 13 Global pen market, by drug type, 2021 - 2033 (USD Billion, Units)
  • Table 14 Key GLP-1 agonist pen products
  • Table 15 Global injectable drug delivery devices market revenue estimates and forecast, by therapeutic use, 2021 - 2033 (USD Billion, Units)
  • Table 16 Global ranking of countries by obesity prevalence (%)
  • Table 17 Global injectable drug delivery devices market revenue estimates and forecast, by end use, 2021 - 2033 (USD Billion, Units)
  • Table 18 Canada regulatory procedure for medical devices
  • Table 19 Cancer statistics and rankings for France, 2022

List of Figures

  • Fig. 1 Injectable drug delivery devices market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based size & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Injectable drug delivery devices market revenue
  • Fig. 9 Volume price analysis
  • Fig. 10 CDMO injectable drug delivery devices market revenue
  • Fig. 11 Market snapshot (regional)
  • Fig. 12 Segment snapshot (product)
  • Fig. 13 Segment snapshot (drug type)
  • Fig. 14 Segment snapshot (therapeutic use)
  • Fig. 15 Segment snapshot (end-use)
  • Fig. 16 Market concentration
  • Fig. 17 Injectable drug delivery devices market dynamics
  • Fig. 18 Injectable drug delivery devices market: PORTER's analysis
  • Fig. 19 Injectable drug delivery devices market: PESTEL analysis
  • Fig. 20 Estimated number of cancer cases in Europe, by Country, 2022 Vs 2025 Vs 2030
  • Fig. 21 Injectable drug delivery devices market, by product: Key takeaways
  • Fig. 22 Injectable drug delivery devices market, by product: Market share, 2025 & 2033
  • Fig. 23 Injectors market, 2021 - 2033 (USD Billion, Units)
  • Fig. 24 Pens market, 2021 - 2033 (USD Billion, Units)
  • Fig. 25 Injectable drug delivery devices market, by drug type: Key takeaways
  • Fig. 26 Injectable drug delivery devices market, by drug type: Market share, 2025 & 2033
  • Fig. 27 GLP-1 agonists market, 2021 - 2033 (USD Billion, Units)
  • Fig. 28 Hormone therapies market, 2021 - 2033 (USD Billion, Units)
  • Fig. 29 Biologics market, 2021 - 2033 (USD Billion, Units)
  • Fig. 30 Others market, 2021 - 2033 (USD Billion, Units)
  • Fig. 31 GLP-1 agonists market, 2021 - 2033 (USD Billion, Units)
  • Fig. 32 Insulin market, 2021 - 2033 (USD Billion, Units)
  • Fig. 33 Hormone therapies market, 2021 - 2033 (USD Billion, Units)
  • Fig. 34 Others market, 2021 - 2033 (USD Billion, Units)
  • Fig. 35 Injectable drug delivery devices market, by therapeutic use: Key takeaways
  • Fig. 36 Injectable drug delivery devices market, by therapeutic use: Market share, 2025 & 2033
  • Fig. 37 Autoimmune disorders market, 2021 - 2033 (USD Billion, Units)
  • Fig. 38 Hormonal disorders market, 2021 - 2033 (USD Billion, Units)
  • Fig. 39 Oncology market, 2021 - 2033 (USD Billion, Units)
  • Fig. 40 Obesity market, 2021 - 2033 (USD Billion, Units)
  • Fig. 41 Diabetes mellitus market, 2021 - 2033 (USD Billion, Units)
  • Fig. 42 Others market, 2021 - 2033 (USD Billion, Units)
  • Fig. 43 Injectable drug delivery devices market, by end use: Key takeaways
  • Fig. 44 Injectable drug delivery devices market, by end use: Market share, 2025 & 2033
  • Fig. 45 Hospitals market, 2021 - 2033 (USD Billion, Units)
  • Fig. 46 Homecare settings market, 2021 - 2033 (USD Billion, Units)
  • Fig. 47 Others market, 2021 - 2033 (USD Billion, Units)
  • Fig. 48 Injectable drug delivery devices market revenue, by region, 2025 & 2033 (USD Billion, Units)
  • Fig. 49 Regional marketplace: Key takeaways
  • Fig. 50 Regional marketplace: Key takeaways
  • Fig. 51 North America injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 52 Estimated number of new cancer cases, by State - 2025
  • Fig. 53 Diagnosed diabetes - total, adults aged 18+ years, age-adjusted percentage (2023)
  • Fig. 54 Reimbursement procurement process
  • Fig. 55 U S injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 56 Diabetes mellitus (types combined), excluding gestational diabetes, age-standardized incidence rate, per 100,000, age 1 year old and older, Canada
  • Fig. 57 Canada injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 58 Mexico injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 59 Europe injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 60 UK injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 61 Germany injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 62 France injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 63 Italy injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 64 Spain injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 65 Sweden injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 66 Norway injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 67 Denmark injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 68 Asia injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 69 China injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 70 Japan injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 71 India injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 72 Thailand injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 73 South Korea pen and injector drug delivery market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 74 Saudi Arabia injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 75 UAE injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 76 Kuwait injectable drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Fig. 77 Key company categorization
  • Fig. 78 Company market share analysis, 2025
  • Fig. 79 Strategy mapping